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Patients with cardiovascular disorders often
need anticoagulation for surgical procedures.
Cardiopulmonary bypass (CPB) usually is per-
formed with unfractionated heparin. Heparin-
induced thrombocytopenia (HIT) is a relatively
common complication of heparin therapy, estimat-
ed to occur among 1% to 2.7% of patients who
receive unfractionated heparin therapy.1-3 In most
cases, the thrombocytopenia in HIT is moderate
without further sequelae. However, 10% to 20% of
patients with HIT have thrombosis that leads to
limb loss or even death.4 Most patients with HIT
have the heparin therapy stopped without sequelae;
these patients should not be reexposed to unfrac-
tionated heparin. A difficult challenge is presented
when these patients need anticoagulation for car-
diovascular surgical procedures.
Ancrod, a fibrinogenolytic enzyme, has been
used successfully during elective CPB for patients
with HIT.5-7 However, defibrinogenation with
Ancrod takes 12 hours, which makes this agent
impractical for use in emergencies.5,6 Iloprost, a car-
bacyclin derivative of prostaglandin I2 (prostacy-
clin), has been shown to inhibit platelet aggregation
and has been used successfully during CPB for
patients with HIT.8-10 Iloprost also causes vasodi-
latation, which has resulted in marked hypotension,
necessitating adrenergic pharmacologic interven-
tion. Fractionated low-molecular-weight heparins
have been used successfully during CPB for
patients.11 However, they frequently cross react with
antibodies to unfractionated heparin.12
Another group of anticoagulants include the
heparinoids. These compounds do not contain
heparin but, instead, contain substances that func-
tion similarly to one or more of the mechanisms of
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3000 units of danaparoid sodium was administered
to the bypass pump, and 9000 units was used to
anticoagulate the patient. One-half hour into the
bypass portion of the operation, an additional 1500
units was administered to the bypass apparatus.
During the surgical procedure, none of the patient’s
recovered blood was reinfused. When the in vivo
anti–factor Xa level declined to 0.57 U/ml, small
clots formed in the filters of the bypass pump, and
an additional 1500 units of danaparoid sodium was
administered into the bypass apparatus. Immediately
after discontinuation of CPB, 150 mg of protamine
sulfate (1.2 mg protamine sulfate per 100 units of
danaparoid sodium) was administered. 
Bypass lasted 2 hours and 45 minutes; the patient
was in the operating room for a total of 7.6 hours.
The procedure had an estimated blood loss of 2500
ml. The patient received 12 units of packed red
blood cells and five 300 ml platelet transfusions intra-
operatively. Postoperatively, bilateral chest tubes
drained 2465 ml of hemorrhagic fluid in 72 hours,
and blood products (eight units of packed red blood
cells and five six-packs of platelets) were administered
within the first 24 postoperative hours. The patient’s
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action of heparin. In this report, we present our
experience using danaparoid sodium (Orgaran), a
heparinoid, as an anticoagulant during CPB for two
patients with HIT. One needed heart transplanta-
tion, and the other needed a coronary artery bypass
graft operation (CABG). In particular, we critically
evaluated intraoperative monitoring assays of dana-
paroid sodium levels during CPB for one of the
patients. 
CASE REPORTS
Patient 1. A 25-year-old man with viral car-
diomyopathy was given intravenous heparin, nitro-
glycerin, captopril, digoxin, furosemide, and aspirin
approximately 2 days before transfer to the University
of Michigan hospital. Heparin anticoagulation was
continued, and within 11 days after admission, the
patient needed placement of a biventricular assist
device (BIVAD) with an intraaortic balloon pump
while awaiting heart transplantation. Anticoagulation
for the BIVAD was with unfractionated heparin and
heparin-bonded plastic tubing. The patient’s hospital
course also included treatment, at various times, with
other medications including diuretics (bumetanide,
metolazone), pressors (dopamine, dobutamine, milri-
none), various antibiotics, captopril, nitroprusside,
procainamide, and benzodiazepines (alprazolam,
diazepam, midazolam). 
While receiving heparin, the patient had a pro-
gressive decrease in platelet count (to 9000/mm3).
The temporal association of the declining platelet
count with the initiation of heparin administration
raised the possibility of HIT. Even though a multi-
factorial cause (for example, sepsis, disseminated
intravascular coagulation, and medications) for the
thrombocytopenia was entertained, a platelet sero-
tonin release assay revealed that in the presence of
either unfractionated heparin or enoxaparin, a drug-
responsive agent in the patient’s plasma induced
secretion of 14C-5-hydroxytryptamine–labeled
donor platelets (Table I). Systemic heparin adminis-
tration was discontinued, but the heparin-bonded
plastic tubing remained attached to the patient and
the BIVAD. Cessation of systemic heparin adminis-
tration was followed by a moderate rise in platelet
count from 9000/mm3 to about 60,000/mm3. In
anticipation of the need for anticoagulation during
cardiac transplantation, danaparoid sodium was
obtained with the patient’s family’s consent and with
approval of the University of Michigan institutional
review board for human studies.
After 4 weeks of use of the BIVAD, a heart
became available for transplantation. Before CPB,
Table I. Heparin-induced serotonin secretion
assay*




















*With heparin-antibody positive plasma, 43% of the 14C-5-
hydroxytryptamine was secreted with 1.25 U/ml standard
heparin; patient plasma alone mixed with donor platelets did not
result in any 14C-5-hydroxytryptamine secretion. 
†Final concentration of heparin or heparinoid in patient or
donor plasma.
‡Percentage secretion was determined with the ratio of 14C-5-
hydroxytryptamine secretion in the patient or donor sample to
14C-5-hydroxytryptamine in a total platelet lysate after the back-
ground was subtracted from both, multiplied by 100.
platelet count normalized after the BIVAD was
removed. Three weeks after transplantation, repair of
a femoral vein pseudoaneurysm necessitated antico-
agulation with a single bolus of 4500 units of dana-
paroid sodium. The patient was discharged 29 days
after cardiac transplantation in good condition.
Patient 2. A 64-year-old woman underwent
percutaneous transluminal coronary angioplasty
during which standard heparin was used. After the
procedure, thrombocytopenia suggested HIT. The
patient had a positive platelet serotonin release assay,
which was performed at another institution.
Danaparoid sodium was obtained for anticoagula-
tion for elective CABG with the patient’s consent
and approval by the institutional review board for
human studies. Approximately 1 hour before CPB
was begun, 5000 units of danaparoid sodium was
administered to this patient, who weighed 92 kg.
Five minutes after administration of the danaparoid
sodium, anti–factor Xa activity was 0.88 U/ml, and
activated clotting time (ACT) was 159 seconds on a
venous sample obtained from the patient. 
Before induced cardioplegia and CPB, an addi-
tional 5000 units of danaparoid sodium was admin-
istered to the patient, and the bypass pump was
primed with 3125 units of danaparoid sodium. An
additional 1875 units of danaparoid sodium was
administered through the bypass pump when it was
found that anti–factor Xa activity was only 0.96
U/ml in a sample obtained from the pump circuit,
and a small clot was identified in a pump reservoir.
For the remainder of CPB, the patient’s anti–factor
Xa activity level remained greater than 1.0 U/ml,
and no further clots were seen. After the four-vessel
CABG was completed, protamine sulfate (1.2
mg/100 units of administered danaparoid sodium)
and calcium chloride (1 gm) were administered at
discontinuation of CPB. 
Bypass lasted 2 hours and 22 minutes during the
5-hour surgical procedure. Intraoperatively, the
patient received four units of packed red blood cells,
one six-pack of platelets, and one unit of fresh frozen
plasma. Postoperative blood loss consisted of 3265
ml of hemorrhagic fluid through bilateral chest
tubes over 72 hours. A total of seven units of packed
red blood cells and two six-packs of platelets were
needed during the postoperative period. The patient
was discharged from the hospital 8 days after CABG
in good condition with a normal platelet count.
METHODS
Platelet serotonin release assay. Heparin-
induced platelet activation was measured in vitro by
performance of a serotonin release assay, designed as
reported by Cines et al.13 and modified by Sheridan
et al.14 and Kelton et al.15 One additional modifica-
tion in the assay was to centrifuge the reacted
platelets over a solution of 0.135 mol/L formalin
and 5 mmol/L ethylenediaminetetraacetic acid
(EDTA).16 Donor platelets for use in this assay were
chosen from a pool of persons who had relative Fc
receptor expression equal to or greater than a known
donor who reacts to heparin-antibody complexes
and who were found at examination to be responsive
to heparin-antibody complexes with known plasmas
that contained antibodies reactive to addition of
heparin.17 Expression of Fc receptors was deter-
mined by means of flow cytometry with a fluorescein
isothiocyanate (FITC)–labeled monoclonal antibody
(IV.3; Medarex, West Lebanon, N.H.) that reacts
with Fcg RII.17
Coagulation assays. Automated ACTs were
obtained at the bedside and in the operating room
with kaolin or celite clotting tubes in a Hemochron
ACT reader (International Technidyne, Edison,
N.J.). For the bedside examinations, ACT was
obtained by means of drawing blood directly into the
clotting tube, which was anticoagulated with 0.625
to 3.75 U/ml danaparoid sodium. Danaparoid sodi-
um (Orgaran) for the in vitro studies was generously
provided by Dr. David A. Leibowitz, Organon Inc.,
West Orange, N.J. Clotting tubes that contained
either kaolin or celite were used in these examina-
tions. Additional examinations were performed with
ACT on samples anticoagulated with danaparoid
sodium and aprotinin 10 to 50 U/ml (Miles
Laboratories, Elkhart, In.). 
Activated partial thromboplastin time (APTT)
was obtained with Actin APTT reagent (Baxter-
Dade, Miami, Fla.) on an MLA 1600 instrument
(Baxter-Dade). Anti–factor Xa activity was measured
with Coatest heparin (Chromogenix AB, Molndal,
Sweden) according to the manufacturer’s instruc-
tions. In determinations of the anti–factor Xa activi-
ty of unfractionated heparin or danaparoid sodium,
the standard curve for the assay was prepared with
each form of the anticoagulant, respectively, in dilu-
tions of 0.2 to 1.0 U/ml. 
RESULTS
Investigations showed that the plasma of
patient 1 was reactive to unfractionated heparin
and enoxaparin (Table I). The modifications of the
serotonin release assay used here were validated
with studies involving multiple donors and
patients. In 78 individual patient evaluations with
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three or more concentrations of heparin in each
evaluation, no sample of donor plasma when incu-
bated with heparin had loss of the serotonin label
more than 1% when centrifuged over the formalin-
EDTA solution (Table I). These data indicated that
the formalin-EDTA solution prevented artifactual
14C-5-hydroxytryptamine loss caused by close con-
tact of platelets during centrifugation.16
At doses of unfractionated heparin in the ther-
apeutic range (0.125 to 0.5 U/ml), 5% to 9% of
the 14C-5-hydroxytryptamine platelet radiolabel
was secreted when the heparin was added to
patient plasma and then incubated with donor
platelets. With any concentration of enoxaparin,
2% to 5% of the 14C-5-hydroxytryptamine radiola-
bel also was secreted. These data are similar to
those we obtained with other patients with sero-
tonin release assays reactive to standard heparin.
Eleven of 12 patients (92%) (other than patient 1)
who had positive results of serotonin release assays
to standard heparin also had positive results to
enoxaparin with our assay. For patient 1 and 12
other patients, danaparoid sodium at any concen-
tration mixed with patient plasma did not activate
donor platelets. These data indicated that dana-
paroid sodium can be used for anticoagulation in
the care of patients with HIT. 
In anticipation of the use of danaparoid sodium
for cardiac transplantation in the care of patient 1,
we performed a number of bedside and laboratory
studies to evaluate various assays for intraoperative
monitoring of this anticoagulant. Examinations were
performed to determine the usefulness of ACT to
assess danaparoid sodium anticoagulation because
ACT is the mainstay of intraoperative monitoring of
heparin therapy during CPB. As the concentration
of danaparoid sodium increased from 0.625 to 3.75
U/ml, there was a linear increase in celite ACT with
an r value of 0.896 (Fig. 1, A). A danaparoid sodi-
um concentration of 1 U/ml gave an ACT of 180
seconds. Values greater than 200 seconds were
equivalent to or greater than 1.5 U/ml of dana-
paroid sodium. Because transplantation was to be
performed with aprotinin, kaolin ACTs were mea-
sured in the presence of 10 and 50 U/ml aprotinin
(Fig. 1, B and C). In the presence of aprotinin,
kaolin ACTs gave the same linearity as celite ACT.
However, with the higher concentration of apro-
tinin, the slope of the ACT curve was not as steep
(Fig. 1, B and C). 
Additional investigations were performed to
determine whether APTT could be a useful clinical
monitor of this anticoagulation, as suggested by
Marshall et al.18 As in vitro concentration of dana-
paroid sodium increased from 0 to 1.0 U/ml,
APTT lengthened from 24 seconds to 45 seconds
in the absence of aprotinin (Fig. 2, A). The
Fig. 1. Effect of danaparoid sodium (Orgaran) on acti-
vated clotting time (ACT). A, Celite ACT with variable
concentrations of danaparoid sodium. B, Kaolin ACT
with 10 U/ml aprotinin and variable concentrations of
danaparoid sodium. C, Kaolin ACT with 50 U/ml apro-
tinin and variable concentrations of danaparoid sodium.
The points on the curve represent individual determina-
tions at each concentration of danaparoid sodium.
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increase in APTT with increasing anticoagulation
was linear with an r value of 0.988. When 50 U/ml
aprotinin was added to the plasma, baseline APTT
values, before any danaparoid sodium was added,
increased to 39 seconds (Fig. 2, A). These data
indicated that aprotinin itself inhibited some of the
coagulation system proteases and prolonged
APTT. As the concentration of danaparoid sodium
increased from 0.2 to 1.0 U/ml, there was pro-
gressive prolongation of APTT to 80 seconds (Fig.
2, A). Thus it appeared that aprotinin proportion-
ately prolonged APTT, but its presence did not
greatly interfere with the linearity or slope of the
APTT prolongation produced by danaparoid sodi-
um alone. In comparison, investigations were per-
formed to show how danaparoid sodium would
decrease hydrolysis of factor Xa (Fig. 2, B). As the
concentration of danaparoid sodium increased
from 0.25 to 1 U/ml, there was a progressive
decrease in factor Xa activity (Fig. 2, B).
All three assays, kaolin ACT, APTT, and
anti–factor Xa assay were conducted every 20 min-
utes during cardiac transplantation (Fig. 3). Twenty
minutes was the minimal turnaround time from
plasma collection to assay results. The kaolin ACT
initially indicated that the patient was anticoagulat-
ed (Fig. 3, A). After administration of danaparoid
sodium, the ACT increased from a preoperative
value of 122 seconds to 217 seconds. However, the
kaolin ACT was found to be otherwise inadequate
to monitor the degree of anticoagulation intraoper-
atively. For example, at 5.08 and 5.55 hours into
the operation, when anti–factor Xa levels were 0.79
and 0.57 U/ml and clots were found in the filters
of the bypass pump, kaolin ACTs were 238 and 266
seconds. These values did not give any indication
that more anticoagulation was needed. A similar in
vivo monitoring inadequacy was determined for
APTT. At 5.08, 5.55, and 6.25 hours, when
anti–factor Xa levels were 0.79, 0.57, and 0.6
U/ml, APTT values were persistently greater than
100 seconds. Only at 6.67 hours, when the
anti–factor Xa level decreased to 0.48 U/ml, did
APTT value begin to shorten to a level of 96.8 sec-
onds. These data indicated that with decreasing
anticoagulation with danaparoid sodium, changes
in APTT lagged behind critical changes in the level
of anti–factor Xa activity. 
With the experience of treating patient 1 with
danaparoid sodium, we planned the treatment of
patient 2 for CABG. We kept the intraoperative
anti–factor Xa level at approximately 1 U/ml. We
accomplished this result by administering a total of
10,000 units of danaparoid sodium to the 92 kg
patient and a total of 3125 units to the priming
solution in the CPB pump. When clotted blood was
found in one of the hemofilters, an additional 1875
Fig. 2. A, Effect of aprotinin and danaparoid sodium
(Orgaran) on APTT. Boxes, APTT obtained in the absence
of aprotinin; circles, APTT obtained in the presence of 50
U/ml aprotinin. The points on the curves represent the
mean of similar duplicates. B, Concentration-dependent
inhibition of bovine factor Xa activity with increased con-
centrations of danaparoid sodium (0.2 to 1.0 U/ml). The
data are mean value ± SEM of six experiments. Samples
that do not show SEM bars were too small to depict. 
used successfully as the sole anticoagulant for
hemodialysis,21,23 deep venous thrombosis,21,24 and
CPB.4,9,18,20-22 It has been recommended that
patients who are to receive danaparoid sodium for
anticoagulation for HIT be examined to determine
whether their platelets also are reactive because of a
small but real risk for cross reaction with heparin-
induced antibodies.25 Among patients with HIT,
the danaparoid sodium cross-reactivity rate has been
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units of danaparoid sodium was administered to the
bypass pump. No further clotting occurred when
anti–factor Xa activity was maintained at greater
than 1.0 U/ml. 
DISCUSSION
Patient 1 had two potential sources of heparin
for the development of HIT, parenteral heparin and
heparin bonded to the tubing of the BIVAD pump.
Previous experience indicates that heparin-coated
catheters can be as likely a source for HIT as the par-
enteral compound.19 The continued thrombocy-
topenia observed in patient 1 despite discontinua-
tion of parenteral heparin was believed to be the
result of continued heparin exposure from the
heparin-coated catheters. The extent of platelet loss
through leaching of heparin from the tubing or
platelet activation by the heparin-bonded tubing
must have been in equilibrium with the patient’s
ability to produce platelets, because platelet count
remained relatively stable at about 50,000/mm3
until transplantation. This assessment was supported
by the fact that full correction of this patient’s
platelet count occurred only with transplantation
and removal of the heparin-bonded tubing attached
to the BIVAD. 
The modified serotonin release assay used in this
study, in which reacted platelets are centrifuged after
they have been fixed with a formalin-EDTA solu-
tion, improves the discriminatory ability of this assay.
This modified procedure prevents artifactual sero-
tonin secretion merely with close contact of activat-
ed platelets during centrifugation.16 This procedure
uniformly results in release of 14C-5-hydroxytrypta-
mine in unactivated platelets of less than 1%, avoid-
ing the necessity for secretion levels greater than
20% to interpret the assay as having a positive
result.14 Therefore any evidence of serotonin release
is indicative of a positive response with this assay. 
Anticoagulation choices for operations on
patients with HIT are limited. Ancrod cannot be
used in emergencies, and Iloprost induces unaccept-
able hypotension. At present, danaparoid sodium is
the most widely available alternative to heparin for
anticoagulation among patients with HIT.4,12,18,20-22
Danaparoid sodium is a mixture of sulfated gly-
cosaminoglucorans isolated and purified from
porcine intestinal mucosa. It contains no heparin.
The average molecular weight is approximately 5500
daltons. The main active components include
heparan sulfate (approximately 84%), dermatan sul-
fate (approximately 12%), and chondroitin sulfate
(approximately 4%). Danaparoid sodium has been
Fig. 3. Intraoperative monitoring of ACT, APTT, and
anti–factor Xa assays. A, Intraoperative ACT. B,
Intraoperative APTT; values shown at 100 seconds actual-
ly represent values greater than 100 seconds. C,
Intraoperative anti–factor Xa activity; values shown at 1
U/ml actually represent values greater than 1 U/ml.
Values plotted for ACT represent single determinations.
Values plotted for the APTT and anti–factor Xa assays rep-
resent means of similar duplicates. 
demonstrated to be less than about 10% compared
with more than 90% cross-reactivity for low-
molecular-weight heparins.
Use of danaparoid sodium as an anticoagulant
during CPB, however, is potentially fraught with
serious difficulties. First, the plasma anti–factor Xa
activity half-life is approximately 25 hours through
either intravenous or subcutaneous routes of admin-
istration.26 Second, no pharmacologic agent avail-
able immediately reverses anticoagulation effects of
danaparoid sodium. Protamine sulfate reverses the
antithrombin activity, not the anti–factor Xa activity,
of heparins and heparinoids. Severe postoperative
bleeding has been reported to occur among 23% of
patients who undergo anticoagulation with dana-
paroid sodium for CPB.26 This information indicat-
ed to us that although adequate anticoagulation can
be achieved with danaparoid sodium, long operative
times to closure and increased bleeding may adverse-
ly influence its potential benefits. 
Our therapeutic goal was to give the minimal
amount of danaparoid sodium that could achieve
adequate anticoagulation. To titrate the level of
danaparoid sodium anticoagulation, reliable intra-
operative assays had to be established. Our data
confirm those from previous studies that suggested
that ACT is linearly prolonged with increasing
danaparoid sodium concentrations in vitro (Fig.
1).4 However, the linearity of this result did not
help predict the in vivo response. Our intraopera-
tive experience with one patient indicated that ACT
cannot be used to predict the actual level of antico-
agulation needed for immediate clinical decisions.
These findings are similar to those of Wilhelm et
al.,22 who reported that for CPB, ACT did not cor-
relate with plasma levels of danaparoid sodium. Our
experience with the two patients described herein,
and with two other patients, indicates that ACT
measurements with danaparoid sodium anticoagu-
lation have no value. This result is different from
the common surgical practice at our institution of
having an ACT of 400 seconds with unfractionated
heparin before initiation of CPB. Results of in vitro
studies similarly suggest that when high doses of
danaparoid sodium are used, APTT lengthens lin-
early in both the absence and the presence of apro-
tinin.18 Our intraoperative experience, however,
indicated that changes in the APTT findings lagged
2 hours behind clinically important changes in
danaparoid sodium levels recognizable with the
anti–factor Xa assay. It is possible that the presence
of aprotinin, which would have fluctuating levels in
vivo, altered the predictability of APTT in estima-
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tion of the level of anticoagulation with danaparoid
sodium. Last, both ACT and APTT results in vivo,
unlike anti–factor Xa levels, are altered by a fre-
quently occurring 40% decline in coagulation factor
levels that occur during CPB.27
Our experience suggests that the only reliable
assay for intraoperative monitoring of the level of
danaparoid sodium anticoagulation is the anti–factor
Xa assay. For this assay to be useful for decision mak-
ing in the operating room, monitoring with mea-
surements every 20 minutes is necessary. Marshall et
al.18 indicated that an anti–factor Xa level of 0.65
U/ml was associated with clots in the bypass exter-
nal filters. Our finding that clots appeared in the fil-
ters when anti–factor Xa level fell to 0.57 U/ml
(patient 1) and 0.96 U/ml (patient 2) indicated that
higher levels of anti-Xa activity are necessary. Similar
findings were documented for two other patients
who underwent CPB in our care. 
Too much danaparoid sodium anticoagulation
can result in prolonged postoperative bleeding. One
patient who had an initial anti–factor Xa level of
1.64 U/ml had excessive postoperative bleeding.
Bleeding associated with high levels of danaparoid
sodium necessitates intensive supportive measures.
Administration of protamine sulfate has no effect on
anti–factor Xa activity. In the operating room, rapid
correction of anticoagulation does occur during
rewarming. Thus, during CPB, intraoperative care
of patients with danaparoid sodium requires careful
steering of anticoagulation between too little and
too much. Although our intraoperative experience is
limited, we currently recommend keeping anti–
factor Xa activity level between more than or equal
to 1.0 and less than 1.5 U/ml during the operative
procedure. This recommendation is consistent with,
but a little more conservative than, the conclusions
proposed by Magnani et al. in their retrospective
review of the cases of 47 patients who underwent
CPB.26
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